Literature DB >> 30416791

The impact of histology and ground-glass opacity component on volume doubling time in primary lung cancer.

Kai Obayashi1,2, Kimihiro Shimizu1,2, Seshiru Nakazawa1,2, Toshiteru Nagashima3, Toshiki Yajima1,2, Takayuki Kosaka1,2, Jun Atsumi1,2, Natsuko Kawatani1,2, Tomohiro Yazawa4, Kyoichi Kaira5, Akira Mogi1,2, Hiroyuki Kuwano1,2.   

Abstract

BACKGROUND: Correlations between volume doubling time (VDT) of primary lung cancer (PLC), histology, and ground glass opacity (GGO) components remain unclear. The purpose of this study was to evaluate and compare VDT of PLC in terms of histology and presence or absence of GGO components.
METHODS: A total of 371 surgically resected PLCs from 2003 to 2015 in our institute were retrospectively reviewed. The VDT was calculated both from the diameters of the entire tumor and of consolidation by using the approximation formula of Schwartz.
RESULTS: The median VDTs of adenocarcinoma, squamous cell carcinoma, and others (large cell neuroendocrine carcinomas, small cell lung carcinomas, pulmonary pleomorphic carcinomas, and large cell carcinomas combined) were 261, 70, and 70 days, respectively; these differ significantly (P<0.001). All PLCs with GGO were adenocarcinomas. The VDT of adenocarcinomas with GGO was significantly longer than that of those without GGO (median VDT: 725 and 177 days, respectively), squamous cell carcinomas, and others. When the VDT calculated from the maximum diameter of consolidation component was compared, adenocarcinomas with GGO also showed significantly slower growth than those without GGO (median VDT: 248 versus 177 days, respectively, P=0.040).
CONCLUSIONS: The VDT of PLCs is longest for adenocarcinomas. VDT was significantly longer in adenocarcinomas with GGO components than in those without such components, irrespective of VDT calculated on the basis of either the entire tumor diameter or consolidation diameter.

Entities:  

Keywords:  Volume doubling time (VDT); adenocarcinoma; ground glass opacity (GGO); primary lung cancer (PLC)

Year:  2018        PMID: 30416791      PMCID: PMC6196174          DOI: 10.21037/jtd.2018.08.118

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  21 in total

Review 1.  The 2004 World Health Organization classification of lung tumors.

Authors:  Mary Beth Beasley; Elisabeth Brambilla; William D Travis
Journal:  Semin Roentgenol       Date:  2005-04       Impact factor: 0.800

2.  Nodule management protocol of the NELSON randomised lung cancer screening trial.

Authors:  Dong Ming Xu; Hester Gietema; Harry de Koning; René Vernhout; Kristiaan Nackaerts; Mathias Prokop; Carla Weenink; Jan-Willem Lammers; Harry Groen; Matthijs Oudkerk; Rob van Klaveren
Journal:  Lung Cancer       Date:  2006-09-20       Impact factor: 5.705

3.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

4.  Growth rate of small lung cancers detected on mass CT screening.

Authors:  M Hasegawa; S Sone; S Takashima; F Li; Z G Yang; Y Maruyama; T Watanabe
Journal:  Br J Radiol       Date:  2000-12       Impact factor: 3.039

5.  The natural history of lung cancer: a review based on rates of tumour growth.

Authors:  D M Geddes
Journal:  Br J Dis Chest       Date:  1979-01

6.  Comparison of actual survivorship after treatment with survivorship predicted by actual tumor-volume doubling time from tumor diameter at first observation.

Authors:  T Mizuno; A Masaoka; H Ichimura; K Shibata; H Tanaka; H Niwa
Journal:  Cancer       Date:  1984-06-15       Impact factor: 6.860

7.  A retrospective study of volume doubling time in surgically resected non-small cell lung cancer.

Authors:  John A Mackintosh; Henry M Marshall; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  Respirology       Date:  2014-05-06       Impact factor: 6.424

8.  Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.

Authors:  Ryota Nakamura; Yoshihisa Inage; Rika Tobita; Kazuko Mori; Takeshi Numata; Hidetoshi Yanai; Takeo Endo; Haruo Ohtani; Hiroaki Satoh; Kenji Yuzawa; Masanori Koizumi; Hamaichi Ueki
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

9.  Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact.

Authors:  Kenji Suzuki; Masahiko Kusumoto; Shun-ichi Watanabe; Ryosuke Tsuchiya; Hisao Asamura
Journal:  Ann Thorac Surg       Date:  2006-02       Impact factor: 4.330

10.  Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.

Authors:  Kazuya Takamochi; Kaoru Mogushi; Hideya Kawaji; Kota Imashimizu; Mariko Fukui; Shiaki Oh; Masayoshi Itoh; Yoshihide Hayashizaki; Weijey Ko; Masao Akeboshi; Kenji Suzuki
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

View more
  7 in total

1.  Cancer Risk in Subsolid Nodules in the National Lung Screening Trial.

Authors:  Mark M Hammer; Lauren L Palazzo; Chung Yin Kong; Andetta R Hunsaker
Journal:  Radiology       Date:  2019-09-17       Impact factor: 11.105

2.  Lung Cancer Radiotherapy: Simulation and Analysis Based on a Multicomponent Mathematical Model.

Authors:  Wen-Song Hong; Shun-Guan Wang; Gang-Qing Zhang
Journal:  Comput Math Methods Med       Date:  2021-04-29       Impact factor: 2.238

3.  Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data.

Authors:  Szu-Chun Yang; Jung-Der Wang; Shi-Yi Wang
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

4.  Subsolid pulmonary nodules: Controversy and perspective.

Authors:  Mark M Hammer; Hiroto Hatabu
Journal:  Eur J Radiol Open       Date:  2020-09-04

5.  Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification.

Authors:  Jung Hee Hong; Samina Park; Hyungjin Kim; Jin Mo Goo; In Kyu Park; Chang Hyun Kang; Young Tae Kim; Soon Ho Yoon
Journal:  Korean J Radiol       Date:  2020-10-30       Impact factor: 3.500

6.  A CT-based nomogram for predicting the risk of adenocarcinomas in patients with subsolid nodule according to the 2021 WHO classification.

Authors:  Qilong Song; Biao Song; Xiaohu Li; Bin Wang; Yuan Li; Wu Chen; Zhaohua Wang; Xu Wang; Yongqiang Yu; Xuhong Min; Dongchun Ma
Journal:  Cancer Imaging       Date:  2022-09-05       Impact factor: 5.605

7.  The growth feature and its diagnostic value for benign and malignant pulmonary nodules met in routine clinical practice.

Authors:  Rui Zhang; Panwen Tian; Zhixin Qiu; Yiying Liang; Weimin Li
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.